Francine Foss

Francine Foss

UNVERIFIED PROFILE

Are you Francine Foss?   Register this Author

Register author
Francine Foss

Francine Foss

Publications by authors named "Francine Foss"

Are you Francine Foss?   Register this Author

100Publications

1892Reads

11Profile Views

A drug safety evaluation of mogamulizumab for the treatment of cutaneous T-Cell lymphoma.

Expert Opin Drug Saf 2019 Sep 17;18(9):769-776. Epub 2019 Jul 17.

b Hematology and Bone Marrow Transplantation, Yale University School of Medicine , New Haven , CT , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14740338.2019.1643837DOI Listing
September 2019

rearrangement in AIDS-associated ALK-negative anaplastic large cell lymphoma.

BMJ Case Rep 2019 Sep 30;12(9). Epub 2019 Sep 30.

Dermatology, Yale University School of Medicine, New Haven, Connecticut, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2019-230641DOI Listing
September 2019

Hepatosplenic T-Cell Lymphomas.

Cancer Treat Res 2019;176:185-193

Hematology and Bone Marrow Transplantation, Yale University School of Medicine, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-99716-2_9DOI Listing
July 2019

The impact of a multimodal approach to vancomycin discontinuation in hematopoietic stem cell transplant recipients (HSCT) with febrile neutropenia (FN).

Transpl Infect Dis 2019 Apr 22;21(2):e13059. Epub 2019 Feb 22.

Department of Pharmacy Services, Yale-New Haven Hospital, New Haven, Connecticut.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/tid.13059DOI Listing
April 2019

Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation.

Ann Hematol 2019 Jan 19;98(1):237-240. Epub 2018 Jul 19.

Section of Hematology/Department of Internal Medicine and Yale Cancer Center, Smilow Cancer Hospital at Yale-New Haven, Yale University School of Medicine, New Haven, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-018-3427-1DOI Listing
January 2019

Cutaneous T-Cell Lymphoma: Trends in Radiation Doses and Patterns of Care 2004-2015.

Anticancer Res 2019 Jan;39(1):253-259

Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, U.S.A.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13105DOI Listing
January 2019

Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate.

Clin Lymphoma Myeloma Leuk 2018 11 27;18(11):e445-e447. Epub 2018 Jun 27.

Yale University School of Medicine, New Haven, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2018.06.020DOI Listing
November 2018

Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma.

J Clin Oncol 2018 Oct 25:JCO1800359. Epub 2018 Oct 25.

Matthew S. Davids, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Gottfried von Keudell, Yale School of Medicine, New Haven, CT; Craig A. Portell, University of Virginia Health System, Charlottesville, VA; Jonathon B. Cohen, Winship Cancer Institute of Emory University, Atlanta, GA; David C. Fisher, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Francine Foss, Yale School of Medicine, New Haven, CT; Andrew W. Roberts, Royal Melbourne Hospital and University of Melbourne, Melbourne, Victoria, Australia; John F. Seymour, Royal Melbourne Hospital, Peter MacCallum Cancer Centre, and University of Melbourne, Melbourne, Victoria, Australia; Rod A. Humerickhouse, AbbVie, Chicago, IL; and Constantine S. Tam, Royal Melbourne Hospital, Peter MacCallum Cancer Centre, St Vincent's Hospital, and University of Melbourne, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.00359
Publisher Site
http://dx.doi.org/10.1200/JCO.18.00359DOI Listing
October 2018

Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma.

Clin Lymphoma Myeloma Leuk 2018 01 6;18(1):e85-e93. Epub 2017 Dec 6.

Hematology and Bone Marrow Transplantation, Yale University School of Medicine, New Haven, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2017.11.004DOI Listing
January 2018

Primary cutaneous aggressive epidermotropic cytotoxic CD8 T-cell lymphoma: long-term remission after brentuximab vedotin.

Int J Dermatol 2017 Dec 19;56(12):1448-1450. Epub 2017 Oct 19.

Hematology and Bone Marrow Transplantation, Yale University School of Medicine, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijd.13792DOI Listing
December 2017

Neurolymphomatosis of the thoracic sympathetic chain.

Neurology 2017 10 22;89(18):1926-1927. Epub 2017 Sep 22.

From the Yale School of Medicine, New Haven, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000004600DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5664295PMC
October 2017

Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sézary Syndrome.

Clin Lymphoma Myeloma Leuk 2017 08 24;17(8):520-526.e2. Epub 2017 Jun 24.

Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2017.05.017DOI Listing
August 2017

Mycosis Fungoides and Sezary Syndrome.

Hematol Oncol Clin North Am 2017 04;31(2):297-315

Department of Dermatology, Yale University School of Medicine, New Haven, CT 06510, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2016.11.008DOI Listing
April 2017

FISH Panel for Leukemic CTCL.

J Invest Dermatol 2017 03 8;137(3):751-753. Epub 2016 Nov 8.

Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jid.2016.10.037DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419071PMC
March 2017

Infusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration.

Support Care Cancer 2017 01 10;25(1):205-208. Epub 2016 Sep 10.

Department of Internal Medicine, Hematology Section, Rutgers-Cancer Institute of New Jersey, New Brunswick, NJ, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00520-016-3399-4
Publisher Site
http://dx.doi.org/10.1007/s00520-016-3399-4DOI Listing
January 2017

Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides.

Clin Lymphoma Myeloma Leuk 2016 11 10;16(11):637-643. Epub 2016 Aug 10.

Kings College London, St John's Institute of Dermatology, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2016.08.009DOI Listing
November 2016

Autologous Stem Cell Mobilization in the Age of Plerixafor.

Clin Lymphoma Myeloma Leuk 2016 07 5;16(7):411-6. Epub 2016 May 5.

Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT; Bloodworks, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2016.04.007DOI Listing
July 2016

The Value and Relevance of the T Cell Lymphoma Registries and International Collaborations: the Case of COMPLETE and the T-Cell Project.

Curr Hematol Malig Rep 2015 Dec;10(4):448-55

Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Centro Oncologico Modenese, Via del Pozzo 71, 41124, Modena, MO, Italy.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11899-015-0291-0
Publisher Site
http://dx.doi.org/10.1007/s11899-015-0291-0DOI Listing
December 2015

Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model.

J Clin Oncol 2015 Nov 5;33(32):3766-73. Epub 2015 Oct 5.

Julia J. Scarisbrick and Felicity Evison, University Hospital Birmingham, Birmingham; Richard Cowan, The Christie Hospital, Manchester; Stephen Morris and Sean J. Whittaker, St Thomas' Hospital, London, United Kingdom; H. Miles Prince and Robert Twigger, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Maarten H. Vermeer and Rein Willemze, Leiden University Medical Centre, Leiden, the Netherlands; Pietro Quaglino, Paolo Fava, and Milena Maule, University of Turin (Torino), Turin; Emilio Berti, Francesco Onida, and Laura Corti, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda Ospedale Maggiore Policlinico, University of Milano-Bicocca, Milan; Nicola Pimpinelli and Vieri Grandi, University of Florence, Florence; Alessandro Pileri and Annalisa Patrizi, University of Bologna, Bologna, Italy; Steven Horwitz and Christiane Querfeld, Memorial Sloan-Kettering Cancer Center, New York, NY; Pierluigi Porcu, Henry Wong, and Kelly Tyler, Ohio State University, Columbus, OH; Gary S. Wood, University of Wisconsin, Madison, WI; Francine Foss and Michael Girardi, Yale University, New Haven, CT; Joan Guitart, Timothy M. Kuzel, and Maria Estela Martinez-Escala, Northwestern University, Chicago, IL; Alain Rook and Ellen Kim, University of Pennsylvania, Philadelphia; PA; Christiane Querfeld, City of Hope Hospital, Duarte; Jinah Kim, Grant Ognibene, Shufeng Li, Mahkam Tavallaee, Richard T. Hoppe, and Youn H. Kim, Stanford University Medical Center, Stanford, CA; Rakhshandra Talpur and Madeleine Duvic, The University of Texas MD Anderson Cancer Center, Houston, TX; Rudolf Stadler and Rene Stranzenbach, Unit University Munster, Minden, Germany; Marie Beylot-Barry and Anne Pham-Ledard, Centre Hospitalier Universitaire Hospital de Bordeaux, Bordeaux; Martine Bagot, Laurence Michel, and Maxime Battistella, Hospital St Louis, Paris, France; Teresa Estrach, Hospital Clínico, University of Barcelona, Villarroel; Octavio Servitje and Cristina Muniesa,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.61.7142DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979132PMC
November 2015

Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.

Oncologist 2015 Sep 22;20(9):1084-91. Epub 2015 Jun 22.

Houston Methodist Cancer Center, Houston, Texas, USA; Yale Cancer Center, New Haven, Connecticut, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0043DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4571813PMC
September 2015

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.

J Clin Oncol 2015 Aug 22;33(23):2492-9. Epub 2015 Jun 22.

Owen A. O'Connor, Columbia University Medical Center; Steven Horwitz, Memorial Sloan Kettering Cancer Center, New York, NY; Tamás Masszi, St Istvan and St Laszlo Hospital, Budapest, Hungary; Achiel Van Hoof, General Hospital St-Jan, Brugge, Belgium; Peter Brown, Rigshospitalet; Poul Knoblauch, Topotarget, Copenhagen, Denmark; Jeannette Doorduijn, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands; Georg Hess, Johannes Gutenberg-University, Mainz, Germany; Wojciech Jurczak, Jagiellonian University, Krakow; Jan Walewski, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warsaw, Poland; Shanta Chawla, Gajanan Bhat, Mi Rim Choi, and Lee F. Allen, Spectrum Pharmaceuticals, Irvine, CA; Kerry Savage, British Columbia Cancer Agency Centre, Vancouver, British Columbia, Canada; Francine Foss, Yale Cancer Center, New Haven, CT; and Andrei Shustov, University of Washington Medical Center, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.2782DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087312PMC
August 2015

Hematopoietic stem cell transplantation for primary cutaneous γδ T-cell lymphoma and refractory subcutaneous panniculitis-like T-cell lymphoma.

J Am Acad Dermatol 2015 Jun;72(6):1010-5.e5

Hematology and Bone Marrow Transplantation, Yale University School of Medicine, New Haven, Connecticut.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2015.01.003DOI Listing
June 2015

A fatal case of primary cutaneous gamma-delta T-cell lymphoma complicated by HLH and cardiac amyloidosis.

Clin Case Rep 2015 Jan 17;3(1):34-8. Epub 2014 Nov 17.

Hematology and Bone Marrow Transplantation, Yale University School of Medicine New Haven, Connecticut.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ccr3.142DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317209PMC
January 2015

Pilot study of sorafenib in relapsed or refractory peripheral and cutaneous T-cell lymphoma.

Br J Haematol 2014 Oct 29;167(1):141-4. Epub 2014 May 29.

Yale University School of Medicine, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.12944DOI Listing
October 2014

Acute toxicity and risk of infection during total skin electron beam therapy for mycosis fungoides.

J Am Acad Dermatol 2013 Oct 9;69(4):537-43. Epub 2013 Jul 9.

Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2013.04.063DOI Listing
October 2013

Polymorphisms in DNA repair pathway genes, body mass index, and risk of non-Hodgkin lymphoma.

Am J Hematol 2013 Jul 30;88(7):606-11. Epub 2013 May 30.

Cancer Institute/Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China; Yale University School of Public Health, New Haven, Connecticut.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23463DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902049PMC
July 2013

Treatment strategies for peripheral T-cell lymphomas.

Authors:
Francine M Foss

Best Pract Res Clin Haematol 2013 Mar 25;26(1):43-56. Epub 2013 May 25.

Yale University School of Medicine, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2013.04.005DOI Listing
March 2013

Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma.

Future Oncol 2013 Jan;9(1):21-9

Department of Internal Medicine (Hematology), Yale University School of Medicine, 333 Cedar Street, PO Box 208032, New Haven, CT 06520, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.12.168DOI Listing
January 2013

Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma.

Authors:
Francine M Foss

Expert Opin Drug Metab Toxicol 2011 Sep 5;7(9):1141-52. Epub 2011 Jul 5.

Yale University School of Medicine, Lymphoma, Leukemia, and Myeloma Program, New Haven, CT 06520-8032, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/17425255.2011.595404DOI Listing
September 2011

Molecular predictors of response in aggressive T-cell lymphomas.

Authors:
Francine M Foss

Cancer J 2011 Mar-Apr;17(2):142-8

Yale University School of Medicine, New Haven, CT 06525, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0b013e31821828b7DOI Listing
July 2011

Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma.

Am J Hematol 2011 Jul 14;86(7):627-30. Epub 2011 Jun 14.

Department of Medical Oncology and Bone Marrow Transplantation, Yale Cancer Center, New Haven, Connecticut 06520, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.22039DOI Listing
July 2011

Hematology: relapsed and refractory PTCL--into the therapeutic abyss.

Authors:
Francine Foss

Nat Rev Clin Oncol 2011 Jun 5;8(6):321-2. Epub 2011 Apr 5.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2011.51DOI Listing
June 2011

Peripheral T-cell lymphoma.

Blood 2011 Jun 14;117(25):6756-67. Epub 2011 Apr 14.

Yale Cancer Center, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2010-05-231548DOI Listing
June 2011

Late afternoon dosing of plerixafor for stem cell mobilization: a practical solution.

Clin Lymphoma Myeloma Leuk 2011 Jun 20;11(3):267-72. Epub 2011 Apr 20.

Section of Hematologic Malignancies, Yale Cancer Center, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2011.03.014DOI Listing
June 2011

Clinical roundtable monograph. T-cell lymphoma: therapeutic overview and disease state awareness.

Clin Adv Hematol Oncol 2010 Dec;8(12 Suppl 22):1-15

Internal Medicine Oncology/Hematology Division University of Nebraska Medical Center Omaha, Nebraska, USA.

View Article

Download full-text PDF

Source
December 2010

Reduced-intensity and nonmyeloablative conditioning regimens.

Cancer Treat Res 2009 ;144:209-32

Medical Oncology and Bone Marrow Transplantation, Yale University School of Medicine, New Haven, CT 06520, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-0-387-78580-6_9DOI Listing
September 2010

Alcohol consumption and non-Hodgkin lymphoma survival.

J Cancer Surviv 2010 Jun 29;4(2):101-9. Epub 2009 Dec 29.

School of Public Health, Yale University, New Haven, CT 06520, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11764-009-0111-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3141078PMC
June 2010

Enhancing existing approaches to peripheral T-cell lymphoma.

Authors:
Francine M Foss

Semin Hematol 2010 Apr;47 Suppl 1:S8-10

Yale Cancer Center, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminhematol.2010.01.012DOI Listing
April 2010

Current and emerging treatment strategies for cutaneous T-cell lymphoma.

Drugs 2010 Feb;70(3):273-86

Hematology/Oncology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2165/11532190-000000000-00000DOI Listing
February 2010

Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma.

Cancer Manag Res 2010 Feb 5;2:53-9. Epub 2010 Feb 5.

Hematology/Oncology, Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA;

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004568PMC
February 2010

Genetic polymorphisms in the metabolic pathway and non-Hodgkin lymphoma survival.

Am J Hematol 2010 Jan;85(1):51-6

Yale University School of Public Health, 60 College Street, New Haven, CT 06520-8034, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.21580DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2964927PMC
January 2010

The importance of accurately characterizing lymphoproliferative disease.

Authors:
Francine M Foss

Oncology (Williston Park) 2009 Nov;23(13):1168, 1170

Medical Oncology and Bone Marrow Transplantation, Yale Cancer Center, New Haven, Connecticut, USA.

View Article

Download full-text PDF

Source
November 2009

Advances in the treatment of T-cell lymphomas.

Authors:
Francine Foss

Clin Adv Hematol Oncol 2009 Oct;7(10 Suppl 18):1-14; quiz 15-6

Lymphoma, Leukemia and Myeloma Program, Yale Cancer Center, New Haven, CT 06520, USA.

View Article

Download full-text PDF

Source
October 2009

Cutaneous T-cell lymphoma.

Hematol Oncol Clin North Am 2008 Oct;22(5):979-96, x

Yale University School of Medicine, 333 Cedar Street, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2008.07.014DOI Listing
October 2008

Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: final results of E1497.

Leuk Lymphoma 2007 Dec 13;48(12):2397-402. Epub 2007 Oct 13.

Feinberg School of Medicine-Northwestern University, Chicago, IL 60611, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190701694186DOI Listing
December 2007

Mycosis fungoides: pathophysiology and emerging therapies.

Semin Oncol 2007 Dec;34(6 Suppl 5):S21-8

Department of Dermatology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2007.11.006DOI Listing
December 2007

Cutaneous T-cell lymphoma: Biologic targets for therapy.

Curr Hematol Malig Rep 2007 Oct;2(4):272-7

Medical Oncology, Yale Cancer Center,Yale School of Medicine, New Haven, CT 06520, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-007-0037-8DOI Listing
October 2007

Efficacy of denileukin diftitox in subcutaneous panniculitis-like T-cell lymphoma.

Clin Lymphoma Myeloma 2007 Sep;7(8):541-5

Department of Dermatology, Yale University School of Medicine, CT 06520-8032, USA.

View Article

Download full-text PDF

Source
September 2007

Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma.

Cancer Treat Rev 2007 Apr 1;33(2):146-60. Epub 2007 Feb 1.

St. John's Institute of Dermatology, Guys and St. Thomas Hospital, Lambeth Palace Road, London SE1 7EH, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2006.08.006DOI Listing
April 2007

Efficacy of low dose clofarabine in refractory precursor T- acute lymphoblastic leukemia.

Yale J Biol Med 2006 Dec;79(3-4):169-72

Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06520, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1994805PMC
December 2006

A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides.

J Am Acad Dermatol 2006 Nov 8;55(5):807-13. Epub 2006 Sep 8.

Department of Dermatology, University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2006.06.038DOI Listing
November 2006

Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox.

Clin Lymphoma Myeloma 2006 Nov;7(3):199-204

Institute for Clinical Research and Health Policy Studies, Tufts New England Medical Center, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S155791901170329
Publisher Site
http://dx.doi.org/10.3816/CLM.2006.n.059DOI Listing
November 2006